Готові списки джерел за темами / Genetically engineered drugs

Добірка наукової літератури з теми "Genetically engineered drugs"

Автор: Grafiati

Опубліковано: 27 травня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Genetically engineered drugs".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Genetically engineered drugs":

Jones-Grizzle, Amy J., and J. Lyle Bootman. "Pharmacoeconomics of Genetically Engineered Drugs." PharmacoEconomics 1, no. 1 (January 1992): 45–53. http://dx.doi.org/10.2165/00019053-199201010-00009.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Kishore, Kamal, and Pawan Krishan. "Pharmacology of recombinant or genetically engineered drugs." Journal of Young Pharmacists 1, no. 2 (2009): 141. http://dx.doi.org/10.4103/0975-1483.55747.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Khobeysh, M. M., and E. V. Sokolovskiy. "Genetically engineered biologics to treat psoriasis. Experience with ustekinumab in an adolescent with severe psoriasis." Meditsinskiy sovet = Medical Council, no. 1 (March 12, 2023): 123–29. http://dx.doi.org/10.21518/ms2023-003.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Modern pathogenetic therapy of psoriasis is the use of suppressive methods aimed to suppress immune reactions in the dermis, synovia, enthesis and eliminate the imbalance between anti-inflammatory and pro-inflammatory cytokines, chemokines. Today, genetically engineered biological drugs are one of the most promising pharmacotherapy achievements for the management of psoriasis, psoriatic arthritis in the group of immunosuppressive agents. Knowing the pathogenetic mechanisms that underlie the development of these diseases allows us today to highly selectively target the top key links of the immunopathogenetic cascade using genetically engineered biologicals, while barely affecting the protective factors of the patient’s immune system unlike the standard backbone (what is referred to as traditional) anti-inflammatory therapy. The treatment of psoriasis in children and adolescents practically involves the same drugs and methods as in adults. However, most of them are used in paediatric practice for conditions for which they are not clearly indicated, and studies on their efficacy and safety are still missing. Currently, it is possible to treat children and adolescents with genetically engineered biological drugs. Ustekinumab, etanercept, adalimumab, secukinumab, and ixekizumab are approved for use in moderate to severe psoriasis in the Russian Federation. In paediatric practice, the genetically engineered biological drug ustekinumab is one of the most effective, safe and convenient for the delivery of therapy (short induction cycle, rare infusions of the drug during maintenance therapy). The article describes the case study of the effective treatment of a 17-year-old patient with severe, continuously recurrent psoriasis. The targeted therapy, including the use of genetically engineered biological drugs, is increasingly being used to treat childhood psoriasis. Moreover, there are now more and more supporters among dermatologists who believe that genetically engineered biological drugs can be prescribed as the first-line drugs for the treatment of moderate to severe psoriasis in children and adolescents.

Матюнова, Алла, Alla Matyunova, Людмила Брегель, and Lyudmila Bregel. "MODERN JUVENILE IDIOPATHIC ARTHRITIS THERAPY OF WITH THE USE OF BIOLOGICAL MEDICATIONS IN A REGIONAL CHILDREN”S 3 LEVEL HOSPITAL - RESULTS AND PROBLEMS." Acta biomedica scientifica 2, no. 5 (January 18, 2018): 102–6. http://dx.doi.org/10.12737/article_5a3a0e4744a0a8.88140750.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Background. Juvenile idiopathic arthritis is accompanied by severe functional disabilities refractory to standard treat- ment with methotrexate. Recently introduced genetic engineering has significantly improved the functional state of the patients with persistent disease and stopped the progressive destruction of joints. However, the risk of adverse reactions against the background of this type of therapy requires further study. Aims: to analyze the efficiency of the genetically engineered drugs applied at juvenile arthritis and undesirable effects of this treatment. Materials and methods. Long-term (7 years) observations of 141 patients aged from 8 months to 18 with juvenile idiopathic arthritis. Results. The article summarizes the experience of successful application of genetically engineered biological preparations (tocilizumab, abatacept, etanercept, adalimumab) in 33 patients out of 141 patients with juvenile arthritis observed in Irkutsk. Serious infections were not registered, but we detected cases of managed neutropenia in 2 out of 12 patients re- ceiving tocilizumab. In one case (3 %) out of 33 patients receiving genetically engineered drugs, the drug was withdrawn because of the risk of tuberculosis. Rare cases of secondary inefficiency of such drugs as abatacept, etanercept, adalimumab have been revealed. The tactics of treating children with undesirable reactions to genetically engineered drugs is described. Conclusions. Genetic engineering therapy has shown a good effect in improving clinical and functional indices and stopping joint destructive damage. However, when using genetically engineered drugs in treatment, the safety issues should be evaluated. Nevertheless, in our study there were no serious adverse events.

Huang, Ya Qiong, Kenneth L. White, De Shun Shi, Xu Jian Chen, Jia Zhou Li, Shi Yuan Zeng, Shi Hua Zhao, and Gui Wen Ruan. "Development and Prospect of Genetically Engineered Pharmaceutics." Advanced Materials Research 746 (August 2013): 588–92. http://dx.doi.org/10.4028/www.scientific.net/amr.746.588.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

With the rapid development of modern biology and technology, Genetically Engineered Pharmaceutics has become the most important field in modern medicinal industry. Currently, we have taken concern that the Genetically Engineered Pharmaceutics has been a subject of research. As advanced genetically engineered technology, genetic therapy, the point mutation techniques, DNA shuffling, RNA interference (RNAi) technology, the bioinformatics for genome and proteome analyses, the high throughput screening technology, etc. can be applied in the treatment of cancer, and other targeted therapies. A great deal of advanced technologies accelerates the development of genetically engineered pharmaceutics, and plays a key role in genetically engineered pharmaceutics. With the advances in genetically engineered pharmaceutics, we look forward to finding more new drugs, such as the high-value peptides, small functional molecular groups, proteins, especially antibodies, vaccines, enzymes, and therapeutic peptides. These developments continue to secure greater health outcomes of human being at all aspects in the long run. In this article, the development and prospect of Genetically Engineered Pharmaceutics are reviewed, and furthermore, the potential development and huge prospects are also presented.

Zyryanov, S. K., and O. I. Butranova. "Genetically engineered drugs for treatment of bronchial asthma: recent achievements." Russian Pulmonology 28, no. 5 (December 24, 2018): 584–601. http://dx.doi.org/10.18093/0869-0189-2018-28-5-584-601.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Current population of patients with asthma is characterized by increasing resistance to standard pharmacotherapeutic agents such as inhaled corticosteroids, antileukotriene agents and anti-IgE antibodies. These findings were confirmed by international statistic data and indicate insufficient efficacy of the treatment. Asthma phenotyping encompassing a role of certain biomarkers for bronchial inflammation could contribute to achieving better response to treatment. Genetically engineered drugs could directly impact on mediators and modulators involved in the inflammation and bronchoconstriction. This is one of the most promising directions of the modern pharmacotherapy, particularly considering severe and difficult-to-treat asthma. A comparative analysis of efficacy and safety of currently available genetically engineered drug groups (monoclonal anti-IgE antibodies, monoclonal antibodies against interleukin (IL)-4/IL-13 and IL-5, and prostaglandin D2 receptor antagonists) was performed by the authors of this article on the basis of results of randomized controlled clinical trials (RCT). According to RCT results, omalizumab is still the leading genetically engineered drug. Moreover, evidence of efficacy and safety of novel agents has been published that allowed implementation these drugs in the routine clinical practice for treatment of severe eosinophilic asthma.

Leonova, K. "Selected problems in the use of genetic engineering biological therapy in patients with rheumatoid arthritis." Clinical Medicine and Pharmacology 6, no. 4 (February 2, 2021): 36–39. http://dx.doi.org/10.12737/2409-3750-2021-6-4-36-39.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Rheumatoid arthritis, like any chronic non-infectious disease, requires constant pharmacological therapy and monitoring of treatment. To relieve exacerbation, maintain long-term remission and improve the quality of life of patients, basic anti-inflammatory drugs are used, which have passed many years of testing for efficacy and safety and are available for patients. But there is a group of drugs that have appeared relatively recently - genetically engineered biological drugs. At the moment, their use is somewhat limited due to the presence of a number of problems. With the accumulation of data on the study of the safety of genetically engineered drugs in the treatment of rheumatoid arthritis, it will be possible to solve many practical issues that arise in the attending physician during the supervision of patients.

Avdeev, Sergey N., Alexandr V. Emelyanov, Oksana M. Kurbacheva, Irina M. Marusenko, Pavel I. Novikov, Olga A. Rizakhanova, and Larisa V. Shul’zhenko. "A new delivery device for benralizumab (autoinjector, pen-injector device) in the clinical practice of treating severe eosinophilic asthma: Conclusion of the Expert Council." PULMONOLOGIYA 31, no. 6 (December 16, 2021): 776–81. http://dx.doi.org/10.18093/0869-0189-2021-31-6-776-781.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

The emergence of new means of administering genetically-engineered biological drugs, such as an autoinjector (pen injector device), can positively affect the organizational aspects of treating patients with severe eosinophilic asthma (SA) who need biological therapy.The aim. To determine the place of a new delivery device for benralizumab (autoinjector, pen injector device) in the clinical practice of treating eosinophilic SA.Results. The expert council considered the results of the latest clinical studies and real practice data on the use of genetically-engineered biological drugs in the form of an autoinjector. The experts discussed the safety and efficacy of this delivery device and recommended considering the possibility of switching eosinophilic SA patients to self-administration of genetically-engineered biological drugs (autoinjector form) at home. This treatment tactic is especially relevant in the current epidemiological situation since it will reduce the risks of infection compared to planned medical care in inpatient or outpatient treatment settings and reduce the burden for healthcare workers.Conclusion. The practice of switching eosinophilic SA patients to self-administration of biologics in the form of an autoinjector (pen injector device) can improve the adherence to biological therapy and quality of life of this group of patients.

Cho, Kyungjoo, Simon Weonsang Ro, Sang Hyun Seo, Youjin Jeon, Hyuk Moon, Do Young Kim, and Seung Up Kim. "Genetically Engineered Mouse Models for Liver Cancer." Cancers 12, no. 1 (December 19, 2019): 14. http://dx.doi.org/10.3390/cancers12010014.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Liver cancer is the fourth leading cause of cancer-related death globally, accounting for approximately 800,000 deaths annually. Hepatocellular carcinoma (HCC) is the most common type of liver cancer, comprising approximately 80% of cases. Murine models of HCC, such as chemically-induced models, xenograft models, and genetically engineered mouse (GEM) models, are valuable tools to reproduce human HCC biopathology and biochemistry. These models can be used to identify potential biomarkers, evaluate potential novel therapeutic drugs in pre-clinical trials, and develop molecular target therapies. Considering molecular target therapies, a novel approach has been developed to create genetically engineered murine models for HCC, employing hydrodynamics-based transfection (HT). The HT method, coupled with the Sleeping Beauty transposon system or the CRISPR/Cas9 genome editing tool, has been used to rapidly and cost-effectively produce a variety of HCC models containing diverse oncogenes or inactivated tumor suppressor genes. The versatility of these models is expected to broaden our knowledge of the genetic mechanisms underlying human hepatocarcinogenesis, allowing the study of premalignant and malignant liver lesions and the evaluation of new therapeutic strategies. Here, we review recent advances in GEM models of HCC with an emphasis on new technologies.

Samigullina, R. R., V. I. Mazurov, and E. A. Trofimov. "Characteristics of complex therapy of immuno-inflammatory rheumatic diseases in COVID-19 pandemic conditions." Russian Medical Inquiry 5, no. 5 (2021): 260–67. http://dx.doi.org/10.32364/2587-6821-2021-5-5-260-267.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

The rapid spread of a new coronavirus infection (COVID-19) requires innovative solutions, including tactics optimization in using genetically engineered and targeted drugs in patients with immuno-inflammatory rheumatic diseases (RD). The authors studied the characteristics of the complex therapy of immuno-inflammatory RD in the COVID-19 pandemic conditions, analyzed the COVID-19 course in patients with RD who received combined therapy with genetically engineered and basic synthetic anti-rheumatic drugs and were under follow-up from March 2020 to March 2021. The researchers found that synthetic basic (methotrexate, leflunomide, etc.), targeted synthetic (tofacitinib, baricitinib, apremilast) and biologic disease-modifying antirheumatic drugs used in the RD treatment, except high-dose glucocorticoids and anti-B cell drugs (rituximab), do not have a negative effect and are not associated with a severe COVID-19 course. The use of interleukin-6 (IL-6) inhibitors is the standard pathogenetic therapy for cytokine release syndrome in COVID-19. Proactive therapy with IL-6 inhibitors provides inhibition of systemic inflammation and contributes to the suppression of cytokine storm syndrome, preventing the development of multiple organ failure and fatal outcome. KEYWORDS: rheumatic diseases, cytokine storm, multiple organ failure, genetically engineered biological drugs, interleukin-6, COVID-19. FOR CITATION: Samigullina R.R., Mazurov V.I., Trofimov E.A. Characteristics of complex therapy of immuno-inflammatory rheumatic diseases in COVID-19 pandemic conditions. Russian Medical Inquiry. 2021;5(5):260–267 (in Russ.). DOI: 10.32364/2587-6821-2021- 5-5-260-267.

Більше джерел

Дисертації з теми "Genetically engineered drugs":

Mustafa, Suhad As'ad. "The development of genetically engineered bacterial enzymes as sensor biological recognition elements for the detection of drugs and explosives." Thesis, Bangor University, 2010. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.540409.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Creedon, Helen. "Use of genetically engineered mouse models in preclinical drug development." Thesis, University of Edinburgh, 2015. http://hdl.handle.net/1842/15911.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

The paucity of well validated preclinical models is frequently cited as a contributing factor to the high attrition rates seen in clinical oncological trials. There remains a critical need to develop models which are accurately able to recapitulate the features of human disease. The aims of this study were to use genetically engineered mouse models (GEMMs) to explore the efficacy of novel treatment strategies in HER2 positive breast cancer and to further develop the model to facilitate the study of mechanisms underpinning drug resistance. Using the BLG--HER2KI-PTEN+/- model, we demonstrated that Src plays an important role in the early stages of tumour development. Chemopreventative treatment with dasatinib delayed tumour inititation (p= 0.046, Wilcoxon signed rank test) and prolonged overall survival (OS) (p=0.06, Wilcoxon signed rank test). Dasatinib treatment also induced squamous metaplasia in 66% of drug treated tumours. We used 2 cell lines derived from this model to further explore dasatinib’s mechanism of action and demonstrated reduced proliferation, migration and invasion following in vitro treatment. Due to the prolonged tumour latency and the low metastatic rate seen in this model, further studies were undertaken with the MMTV-NIC model. This model also allowed us to study the impact of PTEN loss on therapeutic response. We validated this model by treating a cohort of MMTV-NIC PTEN+/- mice with paclitaxel and demonstrated prolonged OS (p=0.035, Gehan Breslow Wilcoxon test). AZD8931 is an equipotent signalling inhibitor of HER2, HER3 and EGFR. We observed heterogeneity in tumour response but overall AZD8931 treatment prolonged OS in both MMTV-NIC PTEN FL/+ and MMTV-NIC PTEN+/- models. PTEN loss was associated with reduced sensitivity to AZD8931 and failure to suppress Src activity, suggesting these may be suitable predictive biomarkers of AZD8931 response. To facilitate further studies exploring resistance, we transplanted MMTV-NIC PTEN+/- fragments into syngeneic mice and generated 3 tumours with acquired resistance to AZD8931. These tumours displayed differing resistance strategies; 1 tumour continued to express HER2 whilst the remaining 2 underwent EMT and lost HER2 expression reflecting to a very limited degree some of the heterogeneity of resistance strategies seen in human disease. To further explore resistance to HER2 targeting tyrosine kinase inhibitors, we generated a panel of human cell lines with acquired resistance to AZD8931 and lapatinib. Western blotting demonstrated loss of HER2, HER3 and PTEN in all resistant lines. Acquisition of resistance was associated with a marked change in phenotype and western blotting confirmed all lines had undergone EMT. We used a combination of RPPA and mass spectrometry to further characterise the AZD8931 resistant lines and identified multiple potential novel proteins involved in the resistant phenotype, including several implicated in EMT. In conclusion, when coupled with appropriate in vitro techniques, the MMTV-NIC model is a valuable tool for selection of emerging drugs to carry forward into clinical trials of HER2 positive breast cancer.

Gning, Fatima. "Construction d’une usine pharmaceutique : impératifs réglementaires, sécuritaires et de rentabilité." Electronic Thesis or Diss., Université Paris-Panthéon-Assas, 2022. http://www.theses.fr/2022ASSA0078.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

L’industrie pharmaceutique est continuellement confrontée à d’importantes mutations qui redéfinissent sans cesse l’équilibre entre la protection de la santé publique et les stratégies de développement économique des sociétés pharmaceutiques. Le marché du médicament est le terrain de forts enjeux économiques pour la France et l’accroissement de ses parts de marché mondial reste une préoccupation majeure. L’atteinte de cet objectif semble se faire autour d’un premier axe ayant trait au développement du génie génétique. Le second axe concerne la construction de nouvelles usines de production à l’échelle nationale et internationale dans le but d’augmenter ses capacités de production. Or, la construction de nouvelles usines pharmaceutiques ayant vocation à concevoir, fabriquer puis commercialiser des médicaments à usage humain s’avère difficultueuse du fait de la conjugaison du droit pharmaceutique, matière ésotérique par nature, et du droit de la construction qui abonde de sujets éminemment techniques. A cela s’ajoute sa finalité qui est d’assurer et préserver la santé du patient tout au long du cycle de vie du médicament, d’innover, d’augmenter les capacités de production, tout en répondant aux plus hauts standards de fabrication. Une telle initiative est d’autant plus audacieuse dans un contexte géopolitique fortement fragilisé par la pandémie de 2020 puis le conflit Russo-Ukrainien qui a exacerbé la pénurie et l’allongement des délais d’approvisionnement de nombreuses matières premières, a provoqué un renchérissement historique de leur coût et de fait, du coût global de réalisation des projets de construction
The pharmaceutical industry is continually confronted with major changes that constantly redefine the balance between the protection of public health and the economic development strategies of pharmaceutical companies. The drug market is the terrain of major economic challenges for France and increasing its global market share remains a major concern. The achievement of this objective seems to be done around a first axis relating to the development of genetic engineering. The second axis concerns the construction of new production plants on a national and international scale in order to increase its production capacities. However, the construction of new pharmaceutical factories intended to design, manufacture and then market drugs for human use is proving difficult due to the combination of pharmaceutical law, an esoteric matter by nature, and construction law, which abounds in subjects that are eminently techniques. Added to this is its purpose, which is to ensure and preserve the health of the patient throughout the life cycle of the drug, to innovate, to increase production capacities, while meeting the highest manufacturing standards. Such an initiative is all the more daring in a geopolitical context strongly weakened by the 2020 pandemic and then the Russo-Ukrainian conflict which exacerbated the shortage and the extension of supply times for many raw materials, caused a historic increase their cost and, in fact, the overall cost of carrying out construction projects

Jung, Lin Wan, and 林婉蓉. "Safety and Quality Regulation of Biomedicine in Taiwan and China: Focus on Genetically Engineered Drug." Thesis, 2015. http://ndltd.ncl.edu.tw/handle/24410564380688915598.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

碩士
國立清華大學
科技法律研究所
103
As the problems of safety and drug tolerance of chemicals get ever more serious, the market of biomedicine grows rapidly to make up for the deficiencies of chemicals in remedial areas. Regulations in Taiwan and China and applications thereof which shall be followed through different stages when promoting genetic engineered medicine into market are discussed in this thesis. Since genetic engineered medicine is categorized as one sort of biomedicine, it should be in accordance with the rules set for biomedicine first and be further considered if regulations targeted to genetic engineered medicine exist. Taiwan and China mainly impose the control of toxicity measurement regarding the rules of content in nonclinical test. Taiwan has further related regulations before entering into nonclinical test, while China does not. The procedural regulations of nonclinical test in Taiwan is mainly stipulated in Good Laboratory Practice, and for China in Good Laboratory Practice (the translation is the same but it is different in Chinese). In Taiwan, Major Review items in Clinical trials of pharmaceuticals is set as the corresponsive rules before biomedicine goes under human clinical test. While in China, Veterinary Drugs Control Act and its Enforcement Statute for are the corresponsive rules thereon. The regulatory framework in Taiwan during clinical test is referred to Good Clinical Practice, and that in China is Good Clinical Practice (the translation is the same but it is different in Chinese). Finally, to ensure the safety of drug usage and increase the quality of medicine, Taiwan and China both make corresponsive regulations in accordance with the International standard of GMP (Good Manufactured Practice). After comparing with the regulations from both countries, it can be found that Taiwan mainly focuses on PIC/S: Guide to Good Manufacturing Practice for Medicinal Products while China concentrates in Good Manufacture Practice of Drugs.

Книги з теми "Genetically engineered drugs":

Copsey, David N., and Sabine Y. J. Delnatte. Genetically Engineered Human Therapeutic Drugs. London: Macmillan Education UK, 1988. http://dx.doi.org/10.1007/978-1-349-09800-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

N, Copsey David, and Delnatte Sabine Y. J, eds. Genetically engineered human therapeutic drugs. New York, N.Y: Stockton Press, 1988.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Dictionary of Genetically Engineered Human Therapeutic Drugs. Pan Macmillan, 1988.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

GOVERNMENT, US. 21st Century Complete Guide to Biotechnology: Federal Research and Regulation, Bioengineered and Genetically Modified (GM) Crops, Seeds, Foods, and Drugs, Genetically Engineered Organisms, Agricultural Biotechnology (DVD-ROM). Progressive Management, 2005.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

US GOVERNMENT. 2005 Biotechnology Encyclopedia: Federal Research and Regulation, Bioengineered and Genetically Modified (GM) Crops, Seeds, Foods, and Drugs, Genetically Engineered (GE) Organisms, Agricultural Biotechnology, FDA, USDA, EPA, NIH, DOE (DVD-ROM). Progressive Management, 2005.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

US GOVERNMENT. 21st Century Essential Guide to Genetic Engineering and Biotechnology: Federal Research and Regulation, Bioengineered and Genetically Modified (GM) Crops, Seeds, Foods, and Drugs, Genetically Engineered (GE) Organisms, Agricultural Biotechnology, FDA, USDA, EPA, NIH, DOE (DVD-ROM). Progressive Management, 2005.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Bates, Gillian P., and Christian Landles. Preclinical Experimental Therapeutics. Oxford University Press, 2014. http://dx.doi.org/10.1093/med/9780199929146.003.0016.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

This chapter begins by reviewing the mammalian models of Huntington’s disease (HD) that have been developed using mice, rats, and a number of large animals, including sheep, pigs, and nonhuman primates. Analysis of these models, together with genetically engineered mice created through specific manipulations of the mouse genome, has provided considerable insights into the molecular pathogenesis of HD. The number of potential therapeutic targets that have been proposed for HD is considerable, and their preclinical evaluation in HD mouse models is being used to select targets that should be pursued in drug development programs. Hence, mouse models have been used extensively to validate therapeutic targets and in the preclinical testing of therapeutic strategies. The limitations of these studies are discussed, and best-practice approaches are highlighted. The chapter concludes with a summary of the gene therapy approaches that are being developed, including strategies to lower the levels of huntingtin.

Частини книг з теми "Genetically engineered drugs":

Hentschel, Christopher. "Overview: Recombinant DNA Proteins and Drug Discovery." In Genetically Engineered Human Therapeutic Drugs, 3–6. London: Macmillan Education UK, 1988. http://dx.doi.org/10.1007/978-1-349-09800-2_1.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Balkwill, Frances R. "Cytokines in Cancer Therapy." In Genetically Engineered Human Therapeutic Drugs, 6–9. London: Macmillan Education UK, 1988. http://dx.doi.org/10.1007/978-1-349-09800-2_2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Duff, Gordon W., Julian A. Symons, and Francesco S. Di Giovine. "Recombinant DNA Proteins and Prospects for Treatment of Inflammatory Diseases." In Genetically Engineered Human Therapeutic Drugs, 9–13. London: Macmillan Education UK, 1988. http://dx.doi.org/10.1007/978-1-349-09800-2_3.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Tuddenham, Edward. "Cardiovascular and Blood-Related Proteins." In Genetically Engineered Human Therapeutic Drugs, 14–16. London: Macmillan Education UK, 1988. http://dx.doi.org/10.1007/978-1-349-09800-2_4.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Gordon, Sarah L. "Overview of Commercial Prospects for Biotechnology Products in Health Care." In Genetically Engineered Human Therapeutic Drugs, 137–42. London: Macmillan Education UK, 1988. http://dx.doi.org/10.1007/978-1-349-09800-2_5.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Gillies, Stephen D. "Designing immunocytokines: genetically engineered fusion proteins for targeted immune therapy." In Recombinant Protein Drugs, 129–47. Basel: Birkhäuser Basel, 2001. http://dx.doi.org/10.1007/978-3-0348-8346-7_6.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Sacca, Rosalba, Sandra J. Engle, Wenning Qin, Jeffrey L. Stock, and John D. McNeish. "Genetically Engineered Mouse Models in Drug Discovery Research." In Methods in Molecular Biology, 37–54. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60761-058-8_3.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Carbajal, Eletha, and Eric C. Holland. "Mouse Models in Preclinical Drug Development: Applications to CNS Models." In Genetically Engineered Mice for Cancer Research, 549–67. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-0-387-69805-2_26.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Loeber, Gerhard, and Renate Schnitzer. "The use of Genetically Engineered Cells in Drug Discovery." In Genetic Engineering, 249–66. Boston, MA: Springer US, 1998. http://dx.doi.org/10.1007/978-1-4899-1739-3_13.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Floyd, Warren, Hsuan-Cheng Kuo, Jonathon E. Himes, Rutulkumar Patel, and David G. Kirsch. "Genetically Engineered Mouse Models for Studying Radiation Biology and Radiosensitizers." In Cancer Drug Discovery and Development, 161–90. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-49701-9_8.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Genetically engineered drugs":

Aksenova, Valentina, Nadezda Klevno, Elena Dementjeva, and Alexey Kazakov. "TB infection in children receiving genetically engineered biologic drugs." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa3626.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Toner, Mehmet. "Moving Living Cells and Fluids on Microchips for Diagnostics." In ASME 2008 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2008. http://dx.doi.org/10.1115/sbc2008-192786.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Biomedical applications of microfabricated devices is no longer limited to non-living systems as genes-on-a-chip or lab-on-a-chip, recent advances in the understanding of cellular behavior in microenvironments have started to pave the way toward living micro-devices. These emerging devices are expected to become key technologies in the 21st century of medicine with a broad range of applications varying from diagnostic, tissue engineered products, cell-based drug screening tools, and basic molecular biology tools. They will also include multiple cell types and/or genetically engineered cells to investigate complex interactions between cells from different tissues. These sophisticated devices will contain micro-engineered tissue units coupled to each other by complex microfluidic handling network. Microfluidic mixing systems will also precisely regulate the composition and concentration of drugs to be tested. This presentation will briefly review the early historical literature on the use of microtechnologies in cellular systems and then focus on various applications in cancer biology, HIV/AIDS and global health, inflammation, and systems biology. The presentation will primarily focus on interesting transport phenomena at the microscale and how such information can be used for the development of microfluidic systems for diagnostics and other applications.

Silva, Maísa de Carvalho, Lariza Laura De Oliveira, and Renato Tinós. "Optimization of Expanded Genetic Codes via Genetic Algorithms." In XV Encontro Nacional de Inteligência Artificial e Computacional. Sociedade Brasileira de Computação - SBC, 2018. http://dx.doi.org/10.5753/eniac.2018.4440.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

In the last decades, researchers have proposed the use of genetically modified organisms that utilize unnatural amino acids, i.e., amino acids other than the 20 amino acids encoded in the standard genetic code. Unnatural amino acids have been incorporated into genetically engineered organisms for the development of new drugs, fuels and chemicals. When new amino acids are incorporated, it is necessary to modify the standard genetic code. Expanded genetic codes have been created without considering the robustness of the code. The objective of this work is the use of genetic algorithms (GAs) for the optimization of expanded genetic codes. The GA indicates which codons of the standard genetic code should be used to encode a new unnatural amino acid. The fitness function has two terms; one for robustness of the new code and another that takes into account the frequency of use of amino acids. Experiments show that, by controlling the weighting between the two terms, it is possible to obtain more or less amino acid substitutions at the same time that the robustness is minimized.

Sharpless, Norman E. "Abstract CN03-01: Drug testing in genetically engineered murine models." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Oct 19-23, 2013; Boston, MA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1535-7163.targ-13-cn03-01.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Qiu, Weiguo, Joseph Cappello, and Xiaoyi Wu. "Fabrication of Genetically Engineered Silk-Elastin-Like Protein Polymer Fibers." In ASME 2008 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2008. http://dx.doi.org/10.1115/sbc2008-190980.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Micro- and submicro-diameter protein fibers are fundamental building blocks of extra- and intra-cellular matrices, providing structural support, stability and protection to cells, tissues and organism [1]. Fabricating performance fibers of both naturally derived and genetically engineered proteins has been extensively pursued for a variety of biomedical applications, including tissue engineering and drug delivery [2]. Silk-elastin-like proteins (SELPs), consisting of tandemly repeated polypeptide sequences derived from silk and elastin, have been biosynthesized using recombinant DNA technique [3]. Their potential as a biomaterials in the form of hydrogels continues to be explored [4, 5]. This study will focus on the fabrication of robust, micro-diameter SELP fibers as biomaterials for tissue engineering applications.

Teng, Weibing, Joseph Cappello, and Xiaoyi Wu. "Viscoelastic Properties of Genetically Engineered Silk-Elastin-Like Protein Polymers." In ASME 2008 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2008. http://dx.doi.org/10.1115/sbc2008-192252.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Genetic engineering of protein-based materials provides material scientists with high levels of control in material microstructures, properties, and functions [1]. For example, multi-block protein copolymers in which individual block may possess distinct mechanical or biological properties have been biosynthesized [2, 3]. Polypeptide sequences derived from well-studied structural proteins (e.g., collagen, silk, elastin) are often used as motifs in the design and synthesis of new protein-based material, in which new functional groups may be incorporated. In this fashion, we have produced a series of silk-elastin-like proteins (SELPs) consisting of polypeptide sequences derived from silk of superior mechanical strength and elastin that is extremely durable and resilient [2, 4]. Notably, the silk-like blocks are capable of crystallizing to form virtual cross-links between elastin-mimetic sequences, which, in turn, lower the crystallinity of the silk-like blocks and thus enhance the solubility of SELPs. Consequently, SELPs may be fabricated into useful structures for biomedical applications, including drug delivery. In this study, we will characterize viscoelastic properties of SELPs, which are particularly relevant to tissue engineering applications.

Lowe, Scott W. "Abstract PL01-03: Drug resistance and tumor maintenance in genetically engineered mice." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 15-19, 2009; Boston, MA. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/1535-7163.targ-09-pl01-03.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Seidel, Diana, Anastasia Shibina, C. Patrick Reynolds, Winfried S. Wels, Nicole Huebener, and Holger N. Lode. "Abstract 2808: GD2-specific genetically engineered NK cell therapy is effective in a drug-resistant neuroblastoma xenograft mouse model." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-2808.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Lee, Edmund Chun Yu, Michael Fitzgerald, Bret Bannerman, Jennifer Terkelsen, Ray Liu, Zhi Li, Mark Manfredi, et al. "Abstract 397: The antitumor activity of the investigational drug MLN9708 in genetically engineered mouse models of plasma cell malignancy." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-397.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Cuppoletti, John. "Composite Synthetic Membranes Containing Native and Engineered Transport Proteins." In ASME 2008 Conference on Smart Materials, Adaptive Structures and Intelligent Systems. ASMEDC, 2008. http://dx.doi.org/10.1115/smasis2008-449.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Our membrane transport protein laboratory has worked with material scientists, computational chemists and electrical and mechanical engineers to design bioactuators and sensing devices. The group has demonstrated that it is possible to produce materials composed native and engineered biological transport proteins in a variety of synthetic porous and solid materials. Biological transport proteins found in nature include pumps, which use energy to produce gradients of solutes, ion channels, which dissipate ion gradients, and a variety of carriers which can either transport substances down gradients or couple the uphill movement of substances to the dissipation of gradients. More than one type of protein can be reconstituted into the membranes to allow coupling of processes such as forming concentration gradients with ion pumps and dissipating them with an ion channel. Similarly, ion pumps can provide ion gradients to allow the co-transport of another substance. These systems are relevant to bioactuation. An example of a bioactuator that has recently been developed in the laboratory was based on a sucrose-proton exchanger coupled to a proton pump driven by ATP. When coupled together, the net reaction across the synthetic membrane was ATP driven sucrose transport across a flexible membrane across a closed space. As sucrose was transported, net flow of water occurred, causing pressure and deformation of the membrane. Transporters are regulated in nature. These proteins are sensitive to voltage, pH, sensitivity to a large variety of ligands and they can be modified to gain or lose these responses. Examples of sensors include ligand gated ion channels reconstituted on solid and permeable supports. Such sensors have value as high throughput screening devices for drug screening. Other sensors that have been developed in the laboratory include sensors for membrane active bacterial products such as the anthrax pore protein. These materials can be self assembled or manufactured by simple techniques, allowing the components to be stored in a stable form for years before (self) assembly on demand. The components can be modified at the atomic level, and are composed of nanostructures. Ranges of sizes of structures using these components range from the microscopic to macroscopic scale. The transport proteins can be obtained from natural sources or can be produced by recombinant methods from the genomes of all kingdoms including archea, bacteria and eukaryotes. For example, the laboratory is currently studying an ion channel from a thermophile from deep sea vents which has a growth optimum of 90 degrees centigrade, and has membrane transport proteins with very high temperature stability. The transport proteins can also be genetically modified to produce new properties such as activation by different ligands or transport of new substances such as therapeutic agents. The structures of many of these proteins are known, allowing computational chemists to help understand and predict the transport processes and to guide the engineering of new properties for the transport proteins and the composite membranes. Supported by DARPA and USARMY MURI Award and AFOSR.